12/13
04:30 pm
otlk
Outlook Therapeutics® Streamlines Operations
Medium
Report
Outlook Therapeutics® Streamlines Operations
12/4
08:12 am
otlk
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD [Yahoo! Finance]
12/4
08:05 am
otlk
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
High
Report
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
12/3
04:32 pm
otlk
Outlook Therapeutics® Announces Executive Leadership Transition [Yahoo! Finance]
High
Report
Outlook Therapeutics® Announces Executive Leadership Transition [Yahoo! Finance]
12/3
04:30 pm
otlk
Outlook Therapeutics® Announces Executive Leadership Transition
Medium
Report
Outlook Therapeutics® Announces Executive Leadership Transition
12/2
02:31 pm
otlk
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
12/2
08:06 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
11/29
08:50 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at BTIG Research from $50.00 to $9.00. They now have a "buy" rating on the stock.
High
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at BTIG Research from $50.00 to $9.00. They now have a "buy" rating on the stock.
11/29
08:01 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/28
12:33 pm
otlk
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study [Yahoo! Finance]
High
Report
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study [Yahoo! Finance]
11/27
11:08 am
otlk
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial [Yahoo! Finance]
Medium
Report
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial [Yahoo! Finance]
11/27
09:36 am
otlk
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? [Yahoo! Finance]
High
Report
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? [Yahoo! Finance]
11/27
06:58 am
otlk
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial [Yahoo! Finance]
High
Report
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial [Yahoo! Finance]
11/27
06:50 am
otlk
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
High
Report
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
11/26
07:55 am
otlk
Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK), [Yahoo! Finance]
Medium
Report
Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK), [Yahoo! Finance]
11/6
08:05 am
otlk
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Low
Report
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
10/18
11:53 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
10/17
09:00 am
otlk
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
Low
Report
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
10/11
09:00 pm
otlk
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm